JP2019500418A - タンパク質を有する局所皮膚組成物および使用方法 - Google Patents
タンパク質を有する局所皮膚組成物および使用方法 Download PDFInfo
- Publication number
- JP2019500418A JP2019500418A JP2018547864A JP2018547864A JP2019500418A JP 2019500418 A JP2019500418 A JP 2019500418A JP 2018547864 A JP2018547864 A JP 2018547864A JP 2018547864 A JP2018547864 A JP 2018547864A JP 2019500418 A JP2019500418 A JP 2019500418A
- Authority
- JP
- Japan
- Prior art keywords
- topical skin
- protein
- skin composition
- skin
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 196
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 159
- 239000000203 mixture Substances 0.000 title claims abstract description 101
- 230000000699 topical effect Effects 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title description 36
- 230000008901 benefit Effects 0.000 claims abstract description 29
- 210000003491 skin Anatomy 0.000 claims description 133
- 230000029663 wound healing Effects 0.000 claims description 27
- 231100000241 scar Toxicity 0.000 claims description 25
- 230000002500 effect on skin Effects 0.000 claims description 18
- 230000019612 pigmentation Effects 0.000 claims description 16
- 239000003981 vehicle Substances 0.000 claims description 14
- 210000002615 epidermis Anatomy 0.000 claims description 13
- 230000000735 allogeneic effect Effects 0.000 claims description 12
- 230000004054 inflammatory process Effects 0.000 claims description 11
- 206010061218 Inflammation Diseases 0.000 claims description 10
- 239000011159 matrix material Substances 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 230000037303 wrinkles Effects 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 6
- 230000003712 anti-aging effect Effects 0.000 claims description 5
- 239000003974 emollient agent Substances 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000008439 repair process Effects 0.000 claims description 5
- 239000002562 thickening agent Substances 0.000 claims description 5
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 230000008591 skin barrier function Effects 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 229940106189 ceramide Drugs 0.000 claims description 3
- 150000001783 ceramides Chemical class 0.000 claims description 3
- 235000004626 essential fatty acids Nutrition 0.000 claims description 3
- 230000003020 moisturizing effect Effects 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000000419 plant extract Substances 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 210000000130 stem cell Anatomy 0.000 claims description 3
- 230000000475 sunscreen effect Effects 0.000 claims description 3
- 239000000516 sunscreening agent Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 230000003556 anti-epileptic effect Effects 0.000 claims 2
- 239000001961 anticonvulsive agent Substances 0.000 claims 2
- 229960003965 antiepileptics Drugs 0.000 claims 2
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 239000000047 product Substances 0.000 description 133
- 210000004027 cell Anatomy 0.000 description 45
- 210000002950 fibroblast Anatomy 0.000 description 40
- 210000001519 tissue Anatomy 0.000 description 38
- 238000004519 manufacturing process Methods 0.000 description 33
- 239000000523 sample Substances 0.000 description 32
- 208000012641 Pigmentation disease Diseases 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 18
- 230000008569 process Effects 0.000 description 17
- 230000001105 regulatory effect Effects 0.000 description 17
- 230000014616 translation Effects 0.000 description 16
- 238000009472 formulation Methods 0.000 description 15
- 230000001976 improved effect Effects 0.000 description 12
- 230000037390 scarring Effects 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 208000032544 Cicatrix Diseases 0.000 description 11
- 230000031018 biological processes and functions Effects 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 230000037387 scars Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000007423 decrease Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 102000008186 Collagen Human genes 0.000 description 9
- 108010035532 Collagen Proteins 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 7
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 7
- 206010040954 Skin wrinkling Diseases 0.000 description 7
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 210000002744 extracellular matrix Anatomy 0.000 description 7
- 238000002493 microarray Methods 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 239000000049 pigment Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 102100031170 CCN family member 3 Human genes 0.000 description 6
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 6
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 6
- 101000665882 Homo sapiens Retinol-binding protein 4 Proteins 0.000 description 6
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 102100038246 Retinol-binding protein 4 Human genes 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000007795 chemical reaction product Substances 0.000 description 6
- 210000004207 dermis Anatomy 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000013411 master cell bank Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 description 5
- 102100030417 Matrilysin Human genes 0.000 description 5
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 5
- 102100026159 Tomoregulin-1 Human genes 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000006978 adaptation Effects 0.000 description 5
- 230000003510 anti-fibrotic effect Effects 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000003796 beauty Effects 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102100023795 Elafin Human genes 0.000 description 4
- 108010014612 Follistatin Proteins 0.000 description 4
- 102000016970 Follistatin Human genes 0.000 description 4
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 description 4
- 101001023986 Homo sapiens Growth/differentiation factor 3 Proteins 0.000 description 4
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 4
- 101000990908 Homo sapiens Neutrophil collagenase Proteins 0.000 description 4
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 4
- 102100030411 Neutrophil collagenase Human genes 0.000 description 4
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- MDCUNMLZLNGCQA-HWOAGHQOSA-N elafin Chemical compound N([C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]2CSSC[C@H]3C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CSSC[C@H]4C(=O)N5CCC[C@H]5C(=O)NCC(=O)N[C@H](C(N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]5N(CCC5)C(=O)[C@H]5N(CCC5)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N4)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N3)=O)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N MDCUNMLZLNGCQA-HWOAGHQOSA-N 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 208000000069 hyperpigmentation Diseases 0.000 description 4
- 230000003810 hyperpigmentation Effects 0.000 description 4
- 230000001969 hypertrophic effect Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000003012 network analysis Methods 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 101150036984 CCN3 gene Proteins 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102100033053 Glutathione peroxidase 3 Human genes 0.000 description 3
- 101001048718 Homo sapiens Elafin Proteins 0.000 description 3
- 101000871067 Homo sapiens Glutathione peroxidase 3 Proteins 0.000 description 3
- 101000998783 Homo sapiens Insulin-like 3 Proteins 0.000 description 3
- 101000979629 Homo sapiens Nucleoside diphosphate kinase A Proteins 0.000 description 3
- 101000979623 Homo sapiens Nucleoside diphosphate kinase B Proteins 0.000 description 3
- 101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 description 3
- 101000834937 Homo sapiens Tomoregulin-1 Proteins 0.000 description 3
- 101000801701 Homo sapiens Tropomyosin alpha-1 chain Proteins 0.000 description 3
- 208000003367 Hypopigmentation Diseases 0.000 description 3
- 102100033262 Insulin-like 3 Human genes 0.000 description 3
- 102100039879 Interleukin-19 Human genes 0.000 description 3
- 238000000585 Mann–Whitney U test Methods 0.000 description 3
- 108700024729 Nephroblastoma Overexpressed Proteins 0.000 description 3
- 102000015532 Nicotinamide phosphoribosyltransferase Human genes 0.000 description 3
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 description 3
- 102100023252 Nucleoside diphosphate kinase A Human genes 0.000 description 3
- 102100023258 Nucleoside diphosphate kinase B Human genes 0.000 description 3
- 102100037499 Parkinson disease protein 7 Human genes 0.000 description 3
- 206010063493 Premature ageing Diseases 0.000 description 3
- 208000032038 Premature aging Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010032428 Protein Deglycase DJ-1 Proteins 0.000 description 3
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 3
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 3
- 102100030758 Sex hormone-binding globulin Human genes 0.000 description 3
- 102100022760 Stress-70 protein, mitochondrial Human genes 0.000 description 3
- 102100033632 Tropomyosin alpha-1 chain Human genes 0.000 description 3
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000005754 cellular signaling Effects 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000008482 dysregulation Effects 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 108010017007 glucose-regulated proteins Proteins 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 239000008241 heterogeneous mixture Substances 0.000 description 3
- 230000003425 hypopigmentation Effects 0.000 description 3
- 208000011379 keloid formation Diseases 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000036548 skin texture Effects 0.000 description 3
- 230000036555 skin type Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- -1 A1M Proteins 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- 102100036723 Discoidin domain-containing receptor 2 Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000929429 Homo sapiens Discoidin domain-containing receptor 2 Proteins 0.000 description 2
- 101001002469 Homo sapiens Interferon lambda-2 Proteins 0.000 description 2
- 101000960946 Homo sapiens Interleukin-19 Proteins 0.000 description 2
- 101000577874 Homo sapiens Stromelysin-2 Proteins 0.000 description 2
- 101000920026 Homo sapiens Tumor necrosis factor receptor superfamily member EDAR Proteins 0.000 description 2
- 102100020989 Interferon lambda-2 Human genes 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 206010023330 Keloid scar Diseases 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 108010031030 Mammaglobin A Proteins 0.000 description 2
- 102000005727 Mammaglobin A Human genes 0.000 description 2
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 2
- 108010001014 Plasminogen Activators Proteins 0.000 description 2
- 102000001938 Plasminogen Activators Human genes 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 230000010799 Receptor Interactions Effects 0.000 description 2
- 102100028848 Stromelysin-2 Human genes 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 101710175559 Tomoregulin-1 Proteins 0.000 description 2
- 102100030810 Tumor necrosis factor receptor superfamily member EDAR Human genes 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000009692 acute damage Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000035614 depigmentation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 230000016788 immune system process Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 2
- 235000019175 phylloquinone Nutrition 0.000 description 2
- 239000011772 phylloquinone Substances 0.000 description 2
- 229960001898 phytomenadione Drugs 0.000 description 2
- 229940127126 plasminogen activator Drugs 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003860 topical agent Substances 0.000 description 2
- 229940025703 topical product Drugs 0.000 description 2
- 210000001260 vocal cord Anatomy 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- RJBSTXIIQYFNPX-UHFFFAOYSA-N 4-methoxy-6-phenyl-1,3,5-triazin-2-amine Chemical compound COC1=NC(N)=NC(C=2C=CC=CC=2)=N1 RJBSTXIIQYFNPX-UHFFFAOYSA-N 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108700016947 Bos taurus structural-GP Proteins 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 108010015972 Elafin Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 1
- 101000853009 Homo sapiens Interleukin-24 Proteins 0.000 description 1
- 101001109792 Homo sapiens Pro-neuregulin-2, membrane-bound isoform Proteins 0.000 description 1
- 101000642453 Homo sapiens Serpin A12 Proteins 0.000 description 1
- 101000829127 Homo sapiens Somatostatin receptor type 2 Proteins 0.000 description 1
- 101100101258 Homo sapiens TYRO3 gene Proteins 0.000 description 1
- 101000796022 Homo sapiens Thioredoxin-interacting protein Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108050009288 Interleukin-19 Proteins 0.000 description 1
- 102100036671 Interleukin-24 Human genes 0.000 description 1
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
- 102100038298 Kallikrein-14 Human genes 0.000 description 1
- 101710115806 Kallikrein-14 Proteins 0.000 description 1
- 102100034866 Kallikrein-6 Human genes 0.000 description 1
- 101710176224 Kallikrein-6 Proteins 0.000 description 1
- 102100034870 Kallikrein-8 Human genes 0.000 description 1
- 101710176225 Kallikrein-8 Proteins 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 102100026553 Mannose-binding protein C Human genes 0.000 description 1
- 101710110798 Mannose-binding protein C Proteins 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 description 1
- 108010029755 Notch1 Receptor Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- UULYVBBLIYLRCU-UHFFFAOYSA-N Palmitinsaeure-n-tetradecylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC UULYVBBLIYLRCU-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102100022668 Pro-neuregulin-2, membrane-bound isoform Human genes 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 102100036400 Serpin A12 Human genes 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 102100023802 Somatostatin receptor type 2 Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 102100031344 Thioredoxin-interacting protein Human genes 0.000 description 1
- 108700036252 Tyrosine Kinase 2 Deficiency Proteins 0.000 description 1
- 102100039127 Tyrosine-protein kinase receptor TYRO3 Human genes 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 108091005605 Vitamin K-dependent proteins Proteins 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000009264 composting Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000036566 epidermal hyperplasia Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000019305 fibroblast migration Effects 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000018615 immunodeficiency 35 Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 230000024181 negative regulation of developmental pigmentation Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000002206 pro-fibrotic effect Effects 0.000 description 1
- 230000007114 proinflammatory cascade Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000037309 reepithelialization Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000037393 skin firmness Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/985—Skin or skin outgrowth, e.g. hair, nails
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/591—Mixtures of compounds not provided for by any of the codes A61K2800/592 - A61K2800/596
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
Abstract
Description
を処置するための局所組成物を提示する。本開示の研究によって見出された、いくつかの所望の利益または特性は、老化または早期老化した皮膚の視覚的徴候を防止すること、低減すること、および/または逆転することである(以降、集合的に「皮膚および関連利益」と呼ぶ)。そのような皮膚および関連利益としては、色素沈着の改善または正常化;バリア機能の改善;真皮マトリックスの改善;表皮または肌質の改善;創傷治癒の促進;瘢痕化の最小化または防止;炎症の低減または排除;皺、皮膚線条、たるんだ皮膚、瘢痕、例えば手術、外傷、ざ瘡、または水痘の瘢痕の処置が挙げられるが、これらに限定されない。
[0133]アッセイを行い、3つの民族的皮膚群(アジア人、アフリカ人、白人/ヨーロッパ系)のうち各々の民族的祖先の要件を満たした健常な志願者の細胞培養物上清6つの試料と、濃縮培地対照1つとを、タンパク質マイクロアレイ(AAH−BLM−1000、RayBiotech、Norcross;GA)によって測定した場合に異なるタンパク質産生レベルについて(1,000種のヒトタンパク質について)検査した。志願者は女性で18〜30歳の範囲の年齢であった。女性を選択したが、男性が志願者として選択されても、またはその組合せでも、同様の結果が得られると考えられる。以下は、RayBiotechによって行われたマイクロアレイプロセスの説明である。Human L−1000アレイを使用する第1工程は、試料中のタンパク質の一級アミンをビオチン化することである。次に、標準的なウェスタンブロットと同様の態様で膜アレイをブロッキングし、予めプリントされたアレイにビオチン標識試料を加える。このアレイは標的タンパク質に特異的な捕捉抗体で予めプリントされており、試料中のタンパク質がインキュベーション期間中にアレイ上の抗体と結合する。HRP共役ストレプトアビジンを使用したインキュベーションの後、化学発光法によってシグナルを可視化し、数量化することができる。アレイの画像を作成し、シグナルの強度を分析する。
アフリカ人:30/1000
白人:88/1000
[0159]平均産生レベルの変化は、プロトコルの定義により、比較対象と比べて25%超の増加/減少と定義される。このデータは、平均産生レベルの変化が、3つ全ての群において、共通した231種の生物学的に有意なタンパク質の変動を示したことを示す。概して、アジア人の試料または皮膚は、アフリカ人および白人の試料または皮膚と比べて低下したタンパク質産生レベルを示したが、白人の皮膚は、産生レベルの最も高い上昇を示した。
[0163]白人(CA)、アフリカ人(AF)、およびアジア人(AS)の3つの民族群間で、皮膚線維芽細胞による全般的遺伝子発現(即ちタンパク質レベル)を比較した。この研究では、各民族性から6人の患者を動員した。各生検から皮膚線維芽細胞を単離し、同様の組織培養条件下で増殖させた。タンパク質を抽出し、インハウスプロトコルに従って、試料をタンパク質アッセイ、試験、および分析にかけた。ここで明記されるように、BioFast Consultant Groupによってデータをさらに補正し、解釈した。
Claims (20)
- 所望の皮膚の利益を達成するように製剤化された局所皮膚組成物であって、
前記局所皮膚組成物の適用によって得られる前記所望の皮膚の利益に基づいて選択されたタンパク質のブレンドと、
前記タンパク質のための送達ビヒクルと
を含み、
前記タンパク質のブレンドのうちの各々が、2体以上の個体を有する同種ドナー群からのものであり、
前記タンパク質のブレンドが、前記局所皮膚組成物の全重量に基づいて0.0001重量%〜10重量%の量で存在する、局所皮膚組成物。 - 前記量が0.001重量%〜5.0重量%である、請求項1に記載の局所皮膚組成物。
- 前記量が0.001重量%〜1.0重量%である、請求項1に記載の局所皮膚組成物。
- 前記同種ドナー群が、アジア人、アフリカ人、および白人からなる群から選択される、請求項1に記載の局所皮膚組成物。
- 前記同種ドナー群が、血統の80%以上が単一の人種または民族性である群を構成するドナーを含む、請求項4に記載の局所皮膚組成物。
- 前記タンパク質が合成的に得られる、請求項1に記載の局所皮膚組成物。
- 前記所望の皮膚の利益が、色素沈着、創傷治癒、炎症、真皮マトリックス、皺、瘢痕防止、および表皮からなる群から選択される少なくとも1つの皮膚効果である、請求項1に記載の局所皮膚組成物。
- 前記局所皮膚組成物がエマルションである、請求項1に記載の局所皮膚組成物。
- 前記エマルションが水中油型エマルションである、請求項8に記載の局所皮膚組成物。
- 前記ビヒクルが、1種以上の抗酸化剤、ポリペプチド、ビタミン、植物抽出物、植物幹細胞由来の材料、油、保存剤、増粘剤、セラミド、スキンライトナー、エクスフォリアント、抗老化および抗皺剤、日焼け止め、皮膚バリア修復剤、保湿成分、必須脂肪酸、保水剤、エモリエント、溶媒、界面活性剤、乳化剤、賦形剤、ポリマー、緩衝剤、温度調節剤など、ならびにそれらの組合せからなる群から選択される、少なくとも1種の成分を含む、請求項1に記載の局所皮膚組成物。
- 前記ビヒクルが水を含み得る、請求項10に記載の局所皮膚組成物。
- 前記ビヒクルが、前記局所皮膚組成物の全重量に基づいて最大99重量%である、請求項11に記載の局所皮膚組成物。
- 所望の皮膚の利益を達成するように製剤化された局所皮膚組成物であって、
前記局所皮膚組成物の適用によって得られる前記所望の皮膚の利益に基づいて選択されたタンパク質のブレンドと、
前記タンパク質のための送達ビヒクルと
を含み、
前記タンパク質のブレンドが、少なくとも2つ以上のドナー群の1体以上のドナーからのものであり、
前記タンパク質のブレンドが、前記局所皮膚組成物の全重量に基づいて0.0001重量%〜10重量%の量で存在する、局所皮膚組成物。 - 前記ドナー群が、異種性であり、アジア人とアフリカ人、アジア人と白人、アフリカ人と白人、およびアジア人とアフリカ人と白人からなる群から選択される、請求項13に記載の局所皮膚組成物。
- 前記量が0.001重量%〜5.0重量%である、請求項13に記載の局所皮膚組成物。
- 前記量が0.001重量%〜1.0重量%である、請求項13に記載の局所皮膚組成物。
- 前記タンパク質が合成的に得られる、請求項13に記載の局所皮膚組成物。
- 前記所望の皮膚の利益が、色素沈着、創傷治癒、炎症、真皮マトリックス、皺、瘢痕防止、および表皮からなる群から選択される少なくとも1つの皮膚効果である、請求項13に記載の局所皮膚組成物。
- 前記局所皮膚組成物がエマルションである、請求項13に記載の局所皮膚組成物。
- 前記ビヒクルが、1種以上の抗酸化剤、ポリペプチド、ビタミン、植物抽出物、植物幹細胞由来の材料、油、保存剤、増粘剤、セラミド、スキンライトナー、エクスフォリアント、抗老化および抗皺剤、日焼け止め、皮膚バリア修復剤、保湿成分、必須脂肪酸、保水剤、エモリエント、溶媒、界面活性剤、乳化剤、賦形剤、ポリマー、緩衝剤、温度調節剤など、ならびにそれらの組合せからなる群から選択される、少なくとも1種の成分を含む、請求項13に記載の局所皮膚組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562261285P | 2015-11-30 | 2015-11-30 | |
US62/261,285 | 2015-11-30 | ||
PCT/US2016/064158 WO2017095887A1 (en) | 2015-11-30 | 2016-11-30 | Topical skin compositions having proteins and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2019500418A true JP2019500418A (ja) | 2019-01-10 |
Family
ID=58776687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018547864A Pending JP2019500418A (ja) | 2015-11-30 | 2016-11-30 | タンパク質を有する局所皮膚組成物および使用方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20170151149A1 (ja) |
EP (1) | EP3383417A4 (ja) |
JP (1) | JP2019500418A (ja) |
KR (1) | KR20180083431A (ja) |
CN (1) | CN108289927A (ja) |
CA (1) | CA3005471A1 (ja) |
HK (1) | HK1256840A1 (ja) |
WO (1) | WO2017095887A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115433776B (zh) * | 2022-09-30 | 2023-12-22 | 中国医学科学院阜外医院 | Ccn3在调控血管平滑肌细胞钙化中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015510884A (ja) * | 2012-03-07 | 2015-04-13 | ファイブロセル テクノロジーズ, インコーポレイテッド | 局所的皮膚用製剤および皮膚の個人向けの処置方法 |
WO2015073778A1 (en) * | 2013-11-14 | 2015-05-21 | Dermarche Labs, Llc | Fibroblast mixtures and methods of making and using the same |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6372494B1 (en) * | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
US20040265268A1 (en) * | 2001-08-18 | 2004-12-30 | Deepak Jain | Compositions and methods for skin rejuvenation and repair |
US20030147830A1 (en) * | 2002-01-30 | 2003-08-07 | The Procter & Gamble Company | Topical skin and/or hair compositions containing protein |
CA2553334C (en) * | 2004-01-16 | 2014-02-25 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Preparation of fibroblast-populated connective tissue substitute |
US20060058238A1 (en) * | 2004-09-15 | 2006-03-16 | Lee Laurent-Applegate | Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same |
CA2658074C (fr) * | 2008-03-17 | 2017-11-07 | L'oreal | Equivalent de peau pigmentee fonctionnelle |
CN114306171A (zh) * | 2011-03-28 | 2022-04-12 | 玫琳凯有限公司 | 局部皮肤用组合物及其用途 |
-
2016
- 2016-11-30 CA CA3005471A patent/CA3005471A1/en not_active Abandoned
- 2016-11-30 WO PCT/US2016/064158 patent/WO2017095887A1/en active Application Filing
- 2016-11-30 KR KR1020187018594A patent/KR20180083431A/ko not_active Application Discontinuation
- 2016-11-30 JP JP2018547864A patent/JP2019500418A/ja active Pending
- 2016-11-30 EP EP16871399.8A patent/EP3383417A4/en not_active Withdrawn
- 2016-11-30 CN CN201680069483.8A patent/CN108289927A/zh active Pending
- 2016-11-30 US US15/365,045 patent/US20170151149A1/en not_active Abandoned
-
2018
- 2018-12-12 HK HK18115925.8A patent/HK1256840A1/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015510884A (ja) * | 2012-03-07 | 2015-04-13 | ファイブロセル テクノロジーズ, インコーポレイテッド | 局所的皮膚用製剤および皮膚の個人向けの処置方法 |
WO2015073778A1 (en) * | 2013-11-14 | 2015-05-21 | Dermarche Labs, Llc | Fibroblast mixtures and methods of making and using the same |
Also Published As
Publication number | Publication date |
---|---|
CN108289927A (zh) | 2018-07-17 |
EP3383417A1 (en) | 2018-10-10 |
HK1256840A1 (zh) | 2019-10-04 |
WO2017095887A1 (en) | 2017-06-08 |
EP3383417A4 (en) | 2019-08-07 |
CA3005471A1 (en) | 2017-06-08 |
US20170151149A1 (en) | 2017-06-01 |
KR20180083431A (ko) | 2018-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hebda | Stimulatory effects of transforming growth factor-beta and epidermal growth factor on epidermal cell outgrowth from porcine skin explant cultures | |
US20190133922A1 (en) | Stem Cell-Derived Exosomes Containing a High Amount of Growth Factors | |
US9381151B2 (en) | Methods and compositions for regenerating and repairing damaged or aged tissue or organs using nonviable irradiated or lyophilized pluripotent stem cells | |
EP2897976B1 (en) | Use of pedf-derived peptides for preventing and/or ameliorating skin aging | |
KR101742629B1 (ko) | 사과줄기세포 추출물을 함유하는 지방유래 줄기세포의 줄기세포성 증진용 조성물 | |
CN101076316B (zh) | 用于促进纤蛋白-5产生和/或提高纤蛋白-5活性的组合物和方法 | |
CN110403907A (zh) | 复合干细胞再生肽混悬剂的用途及其备制 | |
CN109069588A (zh) | 包含gdf11的组合物和其用途 | |
JP2002534454A (ja) | 加齢皮膚の徴候を処置するための組成物におけるロスマリヌス属の植物抽出物の使用 | |
US20200164014A1 (en) | Mesenchymal stem cell attracting agent | |
JP2019031503A (ja) | 線維芽細胞混合物ならびにその作製方法および使用方法 | |
JP2024040280A (ja) | クローナル幹細胞を含むアトピー皮膚炎の予防または治療用薬学的組成物 | |
US20240082134A1 (en) | Compositions and methods of use for treatment or improvement of the condition and appearance of skin | |
KR20100096447A (ko) | 돼지 태반 조직 유래 줄기세포의 배양물 및 그 추출 단백질을 함유한 화장료용 조성물 | |
US20200230172A1 (en) | Stem cell conditioned media for clinical and cosmetic applications | |
JP2019500418A (ja) | タンパク質を有する局所皮膚組成物および使用方法 | |
KR101743488B1 (ko) | 비피더스균 추출물을 함유하는 지방유래 줄기세포의 줄기세포성 증진용 및 피부세포 증식용 조성물 | |
CN107405278B (zh) | 序列为his-d-trp-ala-trp-d-phe-lys-nh2的肽用于减少或延缓细胞衰老的出现和皮肤老化的迹象的用途 | |
CN115363983B (zh) | 龙胆苦苷-圣草枸橼苷复合物及其制备方法和应用 | |
CN108602853A (zh) | 用于预防和根治性治疗脱发的肽 | |
KR101986092B1 (ko) | 유두진피 섬유아세포의 고순도 분리 방법 | |
WO2022019224A1 (ja) | 核酸損傷抑制剤、皮膚外用剤、および核酸損傷抑制方法 | |
JP2023504461A (ja) | 化粧品および医薬品に使用するためのペプチドおよび組成物 | |
KR101871920B1 (ko) | 마이크로 rna를 포함하는 조성물 | |
Jalil | The Influence of Anisotropic Tissue Expander on Nestin and Trkb Expression in Rat Cranio-facial Region. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191113 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200925 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201104 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210204 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210601 |